Neurocrine Biosciences Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
May 1, 2018 7:40 AM EDTDeutsche Bank raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $99.00 (from $97.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Another solid quarter of commercial execution and continued pipeline advancement confirm our bullish outlook on Neurocrine, with continued success of the Ingrezza launch and further revenue... More
Neurocrine Bio. (NBIX) PT Raised to $100 at Baird After Another Beat for Ingrezza
May 1, 2018 7:15 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $84.00) while maintaining an Outperform rating following another strong quarter for Ingrezza.
Analyst Brian Skorney commented, "Investor fears about a quarter of declining sequential growth turned out to be unfounded as... More
